Canopy Growth Heads to Expo West Bringing Lineup of CBD Products and Industry Panel to Show Attendees

Martha Stewart CBD and Quatreau will be on display March 8-12, 2022 at the show in Anaheim, CA

Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC) announced today their participation in Natural Products Expo West 2022. Serving as a Silver Sponsor of the Expo, Canopy Growth's CBD brands, including Martha Stewart CBD and Quatreau will be on display from March 8-12 in Anaheim, CA.

Canopy Growth will also host an industry panel at the show on Thursday, March 10 titled Cannabis Evolution: The Latest Innovations and Trends in CBD and Wellness . With consumers increasingly reaching for CBD products to support wellness, show attendees are invited to join Sol Clahane , Vice President and General Manager for the U.S. Region at Canopy Growth, CJ Rapp, CEO of Karma Culture, the manufacturer of Karma CBD Water , and Jonathan Small , Editor-in-Chief of Green Entrepreneur , for a lively conversation that unpacks CBD wellness trends and highlights innovations powering the CBD space.

"As more consumers continue to enter and explore the CBD category, we're thrilled to be able to showcase our lineup of CBD offerings at Expo West and highlight how each of our brands and formats can address consumers' wellness needs," said Sol Clahane , Vice President and General Manager for the U.S. Region at Canopy Growth. "I'm looking forward to sitting down with my fellow panelists during the show for what I know will be an informative and lively discussion about the CBD industry."

Canopy Growth's portfolio of CBD brands includes Martha Stewart CBD and Quatreau, offering consumers ways to embrace CBD wellness through multiple formats across beverages, edibles, softgels and topicals:

  • Martha Stewart CBD provides consumers with an easy way to manage their wellness throughout the day with convenient and trusted CBD products that are accessible, non-intimidating and delicious. The line includes gummies, oils and softgels, as well as the new line of CBD Wellness Topicals, featuring Super Strength CBD Cream, Sleep Science CBD Cream and Daily De-Stress CBD Cream.
  • Quatreau is a line of premium 20mg CBD-infused sparkling waters that contain the most CBD for the price and are made with zero sugar and simple, natural ingredients. Flavors include Cucumber + Mint, Passionfruit + Guava, Ginger + Lime and Blueberry + Acai.

For more information on Canopy Growth CBD products and where to find them, please visit ShopCanopy.com .

About Canopy Growth
Canopy Growth (TSX:WEED,NASDAQ: CGC ) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, we offer product varieties in high-quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Our global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany. Through our award-winning Tweed and Tokyo Smoke banners, we reach our adult-use consumers and have built a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada, the United States , and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional hemp derived CBD products to the United States through our First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands. For more information visit www.canopygrowth.com .

Notice Regarding Forward-Looking Information
This press release contains "forward-looking statements" and "forward-looking information" within the meaning of applicable U.S. and Canadian securities laws (collectively, "forward-looking statements"), which involve certain known and unknown risks and uncertainties. Forward-looking statements predict or describe our future operations, business plans, business and investment strategies and the performance of our investments. These forward-looking statements are generally identified by their use of such terms and phrases as "intend," "goal," "strategy," "estimate," "expect," "project," "projections," "forecasts," "plans," "seeks," "anticipates," "potential," "proposed," "will," "should," "could," "would," "may," "likely," "designed to," "foreseeable future," "believe," "scheduled" and other similar expressions. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. A discussion of some of the material factors applicable to Canopy Growth Corporation ("Canopy") can be found under the section entitled "Risk Factors" in Canopy's Annual Report on Form 10-K for the year ended March 31, 2021, filed with the Securities and Exchange Commission and with applicable Canadian securities regulators, as such factors may be further updated from time to time in its periodic filings with the Securities and Exchange Commission and with applicable Canadian securities regulators, which can be accessed at www.sec.gov/edgar and www.sedar.com , respectively. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this press release and in the filings. Any forward-looking statement included in this press release is made as of the date of this press release and, except as required by law, Canopy disclaims any obligation to update or revise any forward-looking statement. Readers are cautioned not to put undue reliance on any forward-looking statement. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/canopy-growth-heads-to-expo-west-bringing-lineup-of-cbd-products-and-industry-panel-to-show-attendees-301495447.html

SOURCE Canopy Growth Corporation

News Provided by Canada Newswire via QuoteMedia

WEED:CA,CGC
The Conversation (0)
Gavel resting on cannabis leaves.

Cannabis Crossroads: Record US Demand Meets Federal Gridlock

The US cannabis industry is at a turning point. State-level legalization and retail growth continue to accelerate, but federal policy remains stalled, leaving businesses navigating both opportunity and uncertainty. Record consumer demand is driving sales, yet outdated regulations, restrictive... Keep Reading...
Cannabis leaf.

10 Biggest Cannabis Stocks in the US and Canada in 2025

After initial optimism for rescheduling in the US, the cannabis market has faced challenges in 2025. Despite signs of support from US President Donald Trump and members of his administration, regulatory uncertainty persists in the US. Companies are shifting focus to match changes in consumer... Keep Reading...
Field of cannabis plants under bright sunlight.

Cannabis Market Update: H1 2025 in Review

The first half of 2025 played out differently than many cannabis market participants expected. Heading into the year, there was optimism that rescheduling in the US would reduce or eliminate challenges, but the industry continued to grapple with persistent federal regulatory uncertainty,... Keep Reading...
Closeup of lush green cannabis leaves.

Thailand Reverses Course on Cannabis, Moves to Recriminalize Amid Political Fallout

Thailand’s groundbreaking experiment with cannabis decriminalization is rapidly unraveling, with the government formally moving to reclassify the plant as a narcotic and ban recreational sales.The decision has sent shockwaves through an industry once projected to be worth over US$1 billion.The... Keep Reading...
Cannabis leaf over map of Australia.

A State-by-State Guide to Cannabis in Australia

Australia federally legalised medicinal cannabis in 2016, and Australia's cannabis market has seen major growth since then.Medical cannabis approvals were up by 120 percent in the first half of 2023 compared to the same period in 2022. Statista forecasts that Australian cannabis revenue will... Keep Reading...
Cannabis leaf on road marked with "2025," with sunlight in the background.

New Cannabis Consumption Trends, Regulatory Shifts Seen Driving Market in 2025

Understanding trends in the cannabis industry is paramount for investors eyeing a market with steady growth potential, but the landscape is complex as products and regulations continue to evolve. Consumption habits are changing as edibles, vaping and THC beverages gain traction, especially among... Keep Reading...

Latest Press Releases

Related News